Análisis de la acción Smith & Nephew PLC (SNN)SNNSmith & Nephew PLC

Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

Smith & Nephew PLC (SNN) is currently trading at $30.83, with a forward P/E ratio of 11.16, which suggests it is undervalued compared to the market. However, the RSI is at 88.45, indicating that the stock is overbought in the short term. The company has shown a 6.09% increase over the last five days, but it has a year-to-date decline of 6.23%, reflecting some volatility. Given the mixed earnings report and the significant insider selling (225.80% increase in selling by hedge funds), it may be prudent to hold rather than buy at this time.

4 analysts cover SNN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 35.75.